Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Updated safety findings of PF-07220060 and endocrine therapy in HR+/HER2- breast cancer

Antonio Giordano • 31 May 2024
ASCO 2024
Breast Cancer PF-07220060

Antonio Giordano, MD, PhD, Dana Farber Cancer Institute, Boston, MA, presents updated safety data from a Phase I/IIa study (NCT04557449) of PF-07220060, a selective CDK4 inhibitor, with endocrine therapy in patients with HR+/HER2− metastatic breast cancer. Results from dose-finding cohorts (Parts 1B-C) and results from dose-expansion cohorts (Parts 2B-C) revealed that common treatment-emergent adverse events (TEAEs) included neutropenia, diarrhea, and nausea and there was a low incidence of grade 3 TEAEs. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – Pfizer; Pfizer

More from Antonio Giordano

Evaluating the benefits of selective CDK4 inhibition in HR+/HER2- breast cancer
0:57
Evaluating the benefits of selective CDK4 inhibition in HR+/HER2- breast cancer
Antonio Giordano • 31 May 2024
Phase III trial of PF-07220060 and fulvestrant in HR+/HER2- breast cancer
1:02
Phase III trial of PF-07220060 and fulvestrant in HR+/HER2- breast cancer
Antonio Giordano • 31 May 2024
The future of enfortumab vedotin in triple-negative and HR+/HER2- breast cancer
0:33
The future of enfortumab vedotin in triple-negative and HR+/HER2- breast cancer
Antonio Giordano • 31 May 2024
EV-202: enfortumab vedotin in pretreated HR+/HER2- breast cancer and TNBC
1:25
EV-202: enfortumab vedotin in pretreated HR+/HER2- breast cancer and TNBC
Antonio Giordano • 31 May 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals